Ibuclin Junior

Quick links to important sections

Ibuclin Junior

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ibuclin Junior

Quick Facts

Property Description
Active Ingredients Ibuprofen and Acetaminophen (Paracetamol)
Form Dispersible tablets
Pharmacological Class Combined Analgesic and Antipyretic / NSAID
Common Use Pain relief (analgesia) and fever reduction (antipyresis)
Origin Synthetic

Composition and Identity: A Pediatric Combination

Ibuclin Junior is a fixed-dose combination product containing two distinct synthetic active pharmaceutical ingredients: Ibuprofen and Acetaminophen (Paracetamol). This formulation is designed specifically for the junior patient demographic and is classified as a combined Analgesic and Antipyretic. The use of dispersible tablets facilitates oral administration, offering a key advantage in administering medication to children compared to conventional solid tablets.

The two agents belong to separate pharmacological classes: Ibuprofen is a propionic acid derivative within the Non-Steroidal Anti-Inflammatory Drug (NSAID) class, while Acetaminophen is an aniline derivative primarily known for its central action.


Mechanism and General Purpose

The primary therapeutic purpose of this preparation is to provide effective dual action in achieving pain relief and fever reduction. The medicine is designed to leverage a synergistic effect, where the combined action of the two agents is typically more comprehensive in managing concurrent symptoms than the individual components alone.

The combination provides enhanced efficacy in managing acute pain and fever. Ibuprofen works peripherally to moderate inflammatory processes, while Acetaminophen acts centrally to help modulate the body's core temperature. This dual-pathway approach ensures a robust strategy for symptomatic control.

What side effects are possible with Ibuclin Junior?

Possible Side Effects and Safety Information

The official safety documentation for the Ibuprofen and Acetaminophen combination medicine describes possible adverse reactions categorized by frequency and the body system affected. These classifications are based strictly on regulatory review data (e.g., FDA and EMA/SmPC documents).

Key Adverse Reaction Scope

Adverse reactions are formally grouped into System-Organ Classes (SOCs). Key classes include Gastrointestinal Disorders (e.g., abdominal pain, nausea, vomiting), Hepatobiliary Disorders (concerning the liver), Renal and Urinary Disorders (concerning the kidneys), and Nervous System Disorders (e.g., headache, dizziness).

Many common adverse effects documented are typically gastrointestinal in nature. Less frequent but serious events, such as blood dyscrasias (abnormalities in blood components) and severe hepatic reactions, are classified as rare or very rare in regulatory documents.

Serious Adverse Reactions and Safety Patterns

The regulatory profile explicitly identifies serious reactions, including gastrointestinal ulceration, perforation, and bleeding, severe hepatic toxicity/failure, and acute renal impairment. The NSAID component (Ibuprofen) is associated with an increased risk of cardiovascular thrombotic events (such as stroke) and serious GI events, particularly with higher doses or longer duration of use.

Specific safety considerations are defined for certain groups. Older adults have a documented higher risk of serious GI and renal adverse events. Use is generally restricted or contraindicated in patients with active peptic ulcer, known hypersensitivity, or severe hepatic or renal impairment, as explicitly stated in the official labeling. The medicine's anti-inflammatory properties may also mask the signs of an ongoing infection.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information

The official overdose profile for this combination product focuses on the risks associated with the two active ingredients, defining the documented manifestations and mandatory emergency actions as detailed in government regulatory labeling.

Overdose Scope Regulatory Statement
Documented Presentations Early signs of overdose may include nausea, vomiting, abdominal pain, tiredness, or feeling sleepy [1.1, 2.2]. The initial symptoms may also mimic flu or cold symptoms, and some patients may exhibit no symptoms at all [1.1].
Physiological Systems Affected Overdose carries a risk of severe liver damage and liver failure from the Acetaminophen component, and risk of serious gastrointestinal bleeding (e.g., bloody or black stools) from the Ibuprofen component [1.1, 2.2].
Severity Classification Overdose is classified with the potential for life-threatening outcomes, including death or the need for liver transplantation in severe cases [1.1].
Time-Sensitive Action Prompt medical attention is critical for adults and children even if you do not notice any signs or symptoms [1.1, 2.2].

Official Emergency and Clinical Protocol

When Immediate Medical Help Is Required

The regulatory labeling mandates that if an overdose is suspected, or if signs of severe liver injury (e.g., jaundice) or bleeding (e.g., vomiting blood) occur, the patient must seek emergency medical help or contact a Poison Control Center right away [1.1, 1.2].

Antidote and Monitoring

Management of the Acetaminophen component involves the time-critical administration of the antidote N-acetylcysteine (NAC) to prevent or reduce the severity of liver damage [1.1, 3.2]. Clinical protocol requires monitoring of hepatic and renal function and assaying the acetaminophen concentration in plasma [3.2].

Population-Specific Note

Severe liver damage risk is noted to be increased if the product is taken while consuming three or more alcoholic drinks every day [1.2]. Special considerations are warranted for children, as the reported quantity ingested may be inaccurate [3.4].

Therapeutic Uses of Ibuclin Junior

The primary therapeutic utility of this combination is to provide supportive symptomatic relief across key domains of acute illness and discomfort, helping to ease the overall burden of symptoms. This combination is commonly used to help with symptoms related to systemic imbalance and general physical discomfort, which is particularly relevant in the context of illnesses like the common cold.


Dual Relief for Concurrent Fever and Pain

The medication is applied across domains where additional symptomatic support is needed for symptom clusters that may become intense or disruptive, is used for managing both elevated body temperature and co-existing bodily aches and pain. It is relevant in clinical settings that involve acute or unstable symptom patterns, such as those associated with acute infectious episodes, and is relevant for easing symptoms that create noticeable physiological strain. It may assist with the symptomatic management of conditions characterized by periods of heightened symptoms, including fever, headache, dental pain, and muscular aches.

“The combination contributes to the supportive symptomatic relief it offers when both fever and discomfort are present.”

Management of Acute Aches and Discomfort

This formulation is also used for managing symptoms related to physical discomfort. It is relevant in contexts marked by increased discomfort or tension. Overall, the medication provides support that helps ease the overall symptom burden in conditions characterized by periods of heightened symptoms, contributing to improved comfort and supports general well-being during symptomatic phases. This use is commonly applied when appropriate for situations requiring short-term symptomatic assistance.

Quick Fact Relief for
Primary Domains Fever and Pain Relief
Target Symptoms Bodily aches, headache, dental discomfort, high temperature
Use Context Acute illness, episodic discomfort
Patient Benefit Easing overall symptom burden, supporting comfort

Regulatory References

  1. NIH MedlinePlus overview of cold treatment

Eligibility and Restrictions for Use

Eligibility for Ibuclin Junior — Official Information

Ibuclin Junior, a combination of ibuprofen (an NSAID) and paracetamol, has specific regulatory restrictions on its use based on patient demographics and pre-existing medical conditions.

Eligibility Category Official Status Population/Condition
Pediatric Eligibility Contraindicated/Not Recommended Children under 12 years of age or mathbf40 kg body weight (for the tablet formulation), or under mathbf6 years of age and 20 kg for some components.
Absolute Contraindications Contraindicated Known hypersensitivity to ibuprofen, paracetamol, or other NSAIDs; history of recurrent peptic ulcer/haemorrhage; severe heart failure (NYHA Class IV); severe hepatic or renal failure; active cerebrovascular or other bleeding; and the last trimester of pregnancy.
Use with Caution/Restriction Special Consideration Patients with mild-to-moderate heart, liver, or kidney problems; the elderly; patients with a history of asthma or GI disease; and use in the first and second trimesters of pregnancy.
Physiological State Not Recommended/Use with Caution Pregnancy (especially the last trimester, where it is prohibited) and lactation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Ibuclin Junior is defined by formal regulatory restrictions concerning co-administration with other substances and medications.


Prohibited Combinations and Contraindications

Co-administration of Ibuclin Junior is strictly prohibited with any other medicinal product containing Acetaminophen (Paracetamol) or any other Non-Steroidal Anti-Inflammatory Drug (NSAID). These prohibitions are mandated to prevent exceeding maximum dose limits, which poses a risk of severe hepatic injury and increased incidence of serious gastrointestinal and cardiovascular events. The product is also contraindicated for treating pain following Coronary Artery Bypass Graft (CABG) surgery and in individuals with documented aspirin-sensitive asthma.


Documented Drug Interactions

The product has documented interactions that modify therapeutic efficacy or safety profiles. Co-administration with anticoagulants (such as Warfarin) or corticosteroids is officially noted to reinforce the risk of serious bleeding events. The Ibuprofen component may reduce the therapeutic efficacy of antihypertensive agents and diuretics by diminishing their natriuretic effect. Furthermore, substances that induce the enzyme CYP2E1 may alter Acetaminophen metabolism, increasing its hepatotoxic potential.


Substance and Population Restrictions

The official labeling strictly advises against the consumption of three or more alcoholic drinks daily due to the associated heightened risk of severe liver damage and gastrointestinal bleeding. Geriatric patients (age 60 or older) and individuals with severe renal impairment are documented as having an officially increased susceptibility to interaction-related toxicities.

Mechanism of Action

The mechanism involves the modulation of nociceptive and thermoregulatory signaling pathways through two distinct modes of action. This combination engages two distinct mechanistic domains, influencing pathways both peripherally and centrally.


Modulation of Peripheral Prostaglandin Synthesis

This domain focuses on the action of Ibuprofen, which functions as a non-selective inhibitor of the Cyclooxygenase (COX) enzymes (COX-1 and COX-2). By blocking COX activity, Ibuprofen interrupts the Arachidonic Acid cascade, thereby reducing the synthesis of Prostaglandins (PGE2) at sites of tissue irritation. This mechanism reduces the chemical sensitization of peripheral nociceptors, which attenuates the magnitude of nociceptive input.


Dual Central Action on Thermoregulation and Nociception

This domain combines the primary actions of Acetaminophen and the central effects of Ibuprofen within the CNS. Both agents suppress PGE2 production within the hypothalamus, which causes a return of the elevated core body temperature set point. Additionally, Acetaminophen provides a distinct central mechanism by indirectly modulating descending pain pathways and the endocannabinoid system, which increases the inhibition of nociceptive signal transmission in the spinal cord.

Dosage and Administration Information

The administration of Ibuclin Junior is strictly by the oral route, utilizing the dispersible tablet form. Proper use requires that the tablet unit be reconstituted by fully dispersing it in a specified volume of water immediately prior to consumption. To minimize the potential for gastrointestinal upset, administration is directed to occur with or immediately following food.

The determination of the appropriate amount to administer is fundamentally guided by the child’s body weight, with guidelines advising the use of the lowest effective dose necessary for the intended duration. The medicine is administered on an as-needed basis for the management of acute symptoms, with a specified maximum frequency of three to four times daily. To ensure appropriate component clearance and prevent accumulation, a minimum interval of at least six hours must be maintained between subsequent doses.

Usage is confined to short-term symptomatic management and should not exceed three days without specialized guidance. A key procedural restriction is the prohibition of concurrent use with any other medicines containing either Ibuprofen or Paracetamol, as this risks exceeding the maximum daily amount. Furthermore, there are requirements for dose adjustment in pediatric patients presenting with renal or hepatic impairment, and the product is generally not intended for use in infants under three months of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ibuclin Junior

Evidence for Use in Acute Fever

The evidence supporting the use of the combined components of Ibuclin Junior for fever in children comes primarily from Randomized Controlled Trials (RCTs). These trials, often synthesized in Systematic Reviews and Meta-Analyses, have been applied in studies examining short-term or episodic symptom patterns associated with conditions characterized by fluctuating or episodic manifestations. Researchers focused on outcomes related to systemic or functional imbalance, specifically measuring the Body Temperature in infants and children, typically those aged 6 months to 12 years.

Studies monitored how the children's fever changed in the observed populations, with a focus on documenting measures of temperature change and the time interval for temperature change. Findings describe patterns observed in the studies related to the temperature difference measured and the duration of the observed temperature pattern after administration. One key area where data are still emerging involves the consistency of findings when comparing the combination to treatment with only one of the medicine’s components.


Evidence for Use in Acute Pain and Physical Discomfort

Research has explored the use of the combination’s components in conditions associated with acute or disruptive episodes marked by outcomes related to physical discomfort. This combination was evaluated in studies examining acute pain, such as headache, dental discomfort, and general bodily aches in the pediatric demographic. Trials utilized various patient-reported outcomes describing perceived discomfort and also monitored the need for rescue analgesia.

These studies focused on episodes where symptoms became more noticeable, with findings indicating patterns related to measurements related to pain assessment across different cohorts. Some trials described findings where the time interval evaluated for symptom change was compared to that observed with a control substance. However, there is limited information specifically on the fixed-dose combination structure itself when compared to the individual drugs in studies that measured pain outcomes over the very short-term.


Evidence Quality and Research Gaps

Overall, the research for the components of Ibuclin Junior includes a substantial amount of RCTs and synthesis through Systematic Reviews, but the evidence quality varies across studies when analyzing the comparative findings of the combined formulation versus its individual agents. Long-term effects are not fully established as the follow-up durations were limited in the majority of trials. Studies were not designed to evaluate the durability of the response or the effects of using the combination over an extended period.

Frequently Asked Questions (FAQ)

Common questions about Ibuclin Junior (FAQ)

Q: What are the main differences between Ibuclin Junior and children's paracetamol?

A: Ibuclin Junior is described as a fixed-dose combination product, containing both ibuprofen and acetaminophen. This combination provides a dual mechanism of action for managing pain and fever. In contrast, children's paracetamol (acetaminophen) alone is a single active ingredient and works primarily through central action.

Q: How quickly should I expect Ibuclin Junior to start working?

A: Official information indicates that the combination of active ingredients has been studied to achieve a faster onset of action for pain and fever relief compared to either medicine used alone. The goal of administration is to achieve a change in symptoms within a short timeframe.

Q: How long does the effect of Ibuclin Junior typically last?

A: The official dosing schedule helps determine the duration of the effect. Dosage instructions generally specify administering the medicine every six to eight hours, as needed for ongoing symptoms.

Q: Can Ibuclin Junior cause drowsiness in children?

A: The official safety profile documents possible adverse reactions involving the central nervous system. These Nervous System Disorders may include effects such as headaches or dizziness. The official safety profile documents possible adverse reactions involving the central nervous system, and any pronounced change in behavior or alertness is a factor for observation.

Q: What happens if my child takes Ibuclin Junior with other cold medicines?

A: Regulatory warnings strictly mandate that this medicine must not be used concurrently with any other products containing ibuprofen or acetaminophen (paracetamol). Many cold and flu medicines contain one or both of these ingredients. Using them together risks exceeding the maximum daily amount defined in the official labeling.

Q: Is Ibuclin Junior considered safe for toddlers (under 2 years)?

A: Official product information notes that the medicine is generally not intended for use in infants under three months of age. Eligibility for the specific formulation is based on age and body weight. Use in very young children, including toddlers, is subject to specific professional determination based on the child's individual profile.

Q: Can teenagers use Ibuclin Junior, or is it only for younger children?

A: The official indications state that the product may be used by children 12 years of age and older, provided they meet the specific body weight requirements for the product strength. Older children and teenagers may transition to this or other formulations depending on their needs and weight.

Q: Is Ibuclin Junior available over the counter, or is a prescription needed?

A: Official product approval history indicates that the fixed-dose combination containing ibuprofen and acetaminophen has been authorized by regulatory bodies as an over-the-counter (OTC) medicine. This allows for purchase without a prescription for the temporary relief of pain and fever.

Q: Why is the official guidance on use so specific for children?

A: The official guidance on how to use the medicine is highly specific because the appropriate amount to administer is fundamentally guided by the child's body weight. This precision is required to ensure the lowest effective dose is used, reflecting the differences in how children process medicines compared to adults.

Q: What are common misconceptions about what Ibuclin Junior is used for?

A: Official product labeling strictly defines the accepted uses, which are for pain and fever relief. Misuse errors are commonly related to prohibited co-administration with other medicines containing the same active ingredients, or using the product for conditions listed as absolute contraindications.

Q: Can I give Ibuclin Junior to my child if they have chickenpox?

A: Authoritative health agency guidance suggests that the ibuprofen component of this medicine is typically not recommended for use in children who have chickenpox. This is due to a documented potential association with an increased risk of severe bacterial skin infections.

Q: Is it normal for a child's pain to return right after the effect wears off?

A: Because the medicine is intended for short-term symptomatic management of acute symptoms, the pain or fever is generally expected to return as the medicine is cleared from the body.

Q: Is the liquid form of Ibuclin Junior absorbed differently than the chewable form?

A: Regulatory studies examine whether different oral formulations, such as dispersible tablets or liquids, are bioequivalent. This classification indicates that the different forms are generally considered to have comparable rates and extent of absorption in the body.

Q: Can Ibuclin Junior be used for teething pain?

A: The official labeling states that the product is for the temporary relief of minor aches and pains, which includes symptoms such as toothache. While teething pain is not explicitly listed, its use for this type of minor pain relief is consistent with the medicine's stated purpose.

Q: How is the safety of Ibuclin Junior monitored after it is approved?

A: The safety of approved medicines is continuously monitored through systems established by regulatory bodies, such as the FDA Adverse Event Reporting System. These systems allow healthcare professionals and the public to submit reports of suspected adverse events that occur during the use of the product.

Q: Is Ibuclin Junior similar to the medication adults take, just a lower strength?

A: Ibuclin Junior is a fixed-dose combination product containing two distinct active ingredients (ibuprofen and acetaminophen). While it is formulated for children, its combination structure differs from many common adult pain relievers, which are often single-agent formulations.

Q: Can Ibuclin Junior be used for reducing swelling?

A: The official description of the medicine’s components notes that the ibuprofen element belongs to the class of non-steroidal anti-inflammatory drugs (NSAIDs). This part of the formulation is described as being used to relieve symptoms associated with inflammation and swelling, in addition to pain.

Q: Are there specific warning signs of an interaction with Ibuclin Junior to look for?

A: Official warnings document that signs of severe adverse events, such as feeling faint, vomiting blood, or noticing bloody or black stools, may require immediate cessation of use and professional consultation.

Q: Does Ibuclin Junior contain any common allergens like gluten or lactose?

A: Official product information includes a list of all inactive ingredients, also known as excipients. The presence of common allergens, such as gluten or lactose, is confirmed by reviewing the specific product's inactive ingredients list included in the official labeling.

Q: What is the general expectation for improvement when using Ibuclin Junior for minor injuries?

A: Research has evaluated the use of the combination's components for conditions associated with acute pain and general bodily aches from minor injuries. Studies focused on measuring patient-reported outcomes to describe changes in discomfort levels after administration.

Q: Is it true that Ibuclin Junior is less effective if a child is dehydrated?

A: Official warnings state that conditions like dehydration or hypovolemia (low blood volume) are regulatory factors for consideration prior to administration. While this is primarily a safety precaution related to potential adverse events involving the kidneys, fluid status can affect overall physiological response.

Q: What does the research say about Ibuclin Junior for ear pain?

A: Authoritative medical guidelines confirm that non-opioid pain relievers, including the components of this combination, are often utilized for symptom relief of acute ear pain. The medicine helps manage the pain and inflammation associated with the condition.

How should Ibuclin Junior be stored and disposed of?

Storage and Disposal of Ibuclin Junior

Official regulatory documents define strict storage and disposal requirements for Ibuclin Junior (Ibuprofen and Acetaminophen dispersible tablets).

Detail Regulatory Requirement
Storage Temperature Store at a temperature below 30 C
Container & Protection Keep in the original container/blister pack to protect the tablets from moisture and environmental exposure.
Child Protection Keep out of the sight and reach of children at all times to prevent accidental poisoning.
Disposal Unused medicine must be disposed of via a medicine take-back program.
Environmental Rule Do not throw into wastewater (e.g., flush down the toilet). If take-back is unavailable, dispose of in household trash after mixing with an undesirable substance (e.g., used coffee grounds) and sealing in a container.

These conditions are mandatory to maintain the medicine's chemical stability and potency until its expiration date, as well as to ensure the safe handling of pharmaceutical waste according to federal and local guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ibuclin Junior found in:

A-Z Index: